The chimeric antigen receptor T (CAR-T) cell therapy is a newly developed adoptive
antitumor treatment. Theoretically, CAR-T cells can specifically localize and eliminate tumor …

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a
dismal prognosis. While immunotherapy has been deemed a breakthrough treatment for …

Following immune attack, solid tumors upregulate coinhibitory ligands that bind to inhibitory
receptors on T cells. This adaptive resistance compromises the efficacy of chimeric antigen …

Introduction: Mesothelin (MSLN) is a tumor differentiation antigen normally restricted to the
body's mesothelial surfaces, but significantly overexpressed in a broad range of solid …

Adoptive cellular immunotherapy (ACT) employing engineered T lymphocytes expressing
chimeric antigen receptors (CARs) has demonstrated promising antitumor effects in …

Tumors evade immune destruction by actively inducing immune tolerance through the
recruitment of CD4+ CD25+ Foxp3+ regulatory T cells (Treg). We have previously described …

Purpose: Surgical resection provides the only possibility of cure for pancreas cancer. A
standard adjuvant approach has not been established. We tested the safety and efficacy of a …

Background Gastrointestinal (GI) cancers are the most common human tumors encountered
worldwide. The majority of GI cancers are unresectable at the time of diagnosis, and in the …

Mesothelin (MSLN) and cancer antigen125/mucin 16 (CA125/MUC16) are potential
biomarkers for pancreatic cancer (PC) that are co-overexpressed at the invading edges of …

Background MicroRNAs (miRNAs) are involved in cancer pathogenesis, apoptosis, and cell
growth, thereby functioning as tumor suppressors or oncogenes. However, expression …